Replies to post #23807 on The Rising Influence of Rising Affluence

[DewDiligence]

The 34% drop in colonoscopies (from 2019 to 2020) is partially attributable to the continued uptake of the Cologuard test.

[DewDiligence]

ABT says current procedure volume for its medical devices is +3% from pre-COVID period (early 2020).

[DewDiligence]

ZBH issues_2021_guidance—>12.5-15.5%_YoY_revenue_growth_in_constant_currency:

https://investor.zimmerbiomet.com/~/media/Files/Z/ZimmerBiomet-IR/press-release/q1-2021-earnings-release.pdf

“Our performance was stronger than we anticipated in the first quarter, as we saw signs of the pandemic beginning to subside across many regions toward the end of the quarter driven by acceleration of vaccine rollout. As we move into the second quarter, we expect that momentum to continue and believe we are well-positioned to meet the needs of our customers as elective procedures return," said Bryan Hanson, President and CEO of Zimmer Biomet.